Matin Burrow
DMB-Diagnostics GmbH, Germany
Title: New method of quantitative, circulating tumor cell (CTC) diagnostic, treatment selection, monitoring and surveillance with superior outcome for the patient
Biography
Biography: Matin Burrow
Abstract
Maintrac® is a laboratory based method to quantify in a reproducible manner living circulating tumor cells. This wayrnit is possible to do further analytic with these cells. Be it molecular genetic testing of certain tumor characteristics orrnsurface protein determination for real pharmaceutical target identification. Since these CTCs are alive, it is possible to checkrnall different chemot
Maintrac® is a laboratory based method to quantify in a reproducible manner living circulating tumour cells. This way it is possible to do further analytic with these cells. Be it molecular genetic testing of certain tumour characteristics or surface protein determination for real pharmaceutical target identification. Since these CTCs are alive, it is possible to checkrnall different chemotherapeutics and their killing rate on these CTCs. Best working medications can be selected before starting aggressive chemotherapies. Furthermore, it is possible to monitor treatment success “just” by quantifying CTC over the cause of the therapy. Even during and after endocrine therapy, it is possible to show how long to give i.e., Tamoxifen or when to switch to other, more efficient medication in case the cell number is increasing. This method was developed over the last decade and work on all tumours deriving from epithelial origin (almost all solid tumours). We showed in several clinical trials with >650 patients and >100,000 measurement significant improvement for patients and the overall relapse free survival while being monitored with this method. Maintrac® is nowadays already used in clinical routine in ~30 countries worldwide.
Therapeutics and their killing rate on these CTCs. Best working medications can be selected before startingrnaggressive chemotherapies. Furthermore, it is possible to monitor treatment success “just” by quantifying CTC over the causernof the therapy. Even during and after endocrine therapy, it is possible to show how long to give i.e., Tamoxifen or when to switchrnto other, more efficient medication in case the cell number is increasing. This method was developed over the last decade andrnwork on all tumors deriving from epithelial origin (almost all solid tumors). We showed in several clinical trials with >650rnpatients and >100,000 measurement significant improvement for patients and the overall relapse free survival while beingrnmonitored with this method. Maintrac® is nowadays already used in clinical routine in ~30 countries worldwide.
Speaker Presentations
Speaker PPTs Click Here